Press Release
Walden Biosciences Announces Key Initiatives to Advance Clinical Pipeline and Support Phase 2 Program for WAL0921 in Rare Kidney Diseases
September 4, 2025
Walden Biosciences Appoints Howard Mayer, M.D. to Board of Directors
January 28, 2025
Walden Biosciences Highlights 2024 Accomplishments and 2025 Priorities
January 10, 2025
Walden Biosciences Fully Enrolls First Cohort in Phase 2 Basket Study of WAL0921 in Chronic Kidney Diseases
September 30, 2024
Walden Biosciences Announces Research Collaboration with World Renowned Genetic Epidemiologist to Advance Work on Causal Role of suPAR in Chronic Kidney Disease
May 13, 2024
Walden Biosciences Announces Positive Topline Data from Phase 1+ Clinical Study of WAL0921 in Development for Treatment of Kidney Diseases
April 15, 2024
